Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial
Nature Medicine · 2025-04 · 31 (4) · 1120-1124
DOI: 10.1038/s41591-024-03486-6 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Nature Medicine, online erschienen am 24.01.2025. Verfasst von Christian Kurzeder und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Gynecologic Oncology, University Hospital Basel, University of Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Digoxin, Breast Neoplasms, Neoplastic Cells, Circulating. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - E…, Wellcome Trust.
Abstract (Originalsprache)
The presence of circulating tumor cell (CTC) clusters is associated with disease progression and reduced survival in a variety of cancer types. In breast cancer, preclinical studies showed that inhibitors of the Na + /K + ATPase suppress CTC clusters and block metastasis. Here we conducted a prospective, open-label, proof-of-concept study in women with metastatic breast cancer, where the primary objective was to determine whether treatment with the Na + /K + ATPase inhibitor digoxin could reduce mean CTC cluster size. An analysis of nine patients treated daily with a maintenance digoxin dose (0.7–1.4 ng ml −1 serum level) revealed a mean cluster size reduction of −2.2 cells per cluster upon treatment ( P = 0.003), meeting the primary endpoint of the study. Mechanistically, transcriptome profiling of CTCs highlighted downregulation of cell–cell adhesion and cell-cycle-related genes upon treatment with digoxin, in line with its cluster-dissolution activity. No treatment-related adverse events occurred. Thus, our data provide a first-in-human proof of principle that digoxin treatment leads to a partial CTC cluster dissolution, encouraging larger follow-up studies with refined Na + /K + ATPase inhibitors and that include clinical outcome endpoints. ClinicalTrials.gov identifier: NCT03928210 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Gynecologic Oncology, University Hospital Basel, University of Basel, Basel, Switzerland.
- Department of Gynecology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
- Department of Biology, Institute of Molecular Health Sciences, Swiss Federal Institute of Technology, Zurich, Switzerland.
- Department of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
- Center of Oncology and Hematology, Medical University Clinic, Kantonsspital Baselland, Liestal, Switzerland.
- Breast Center, University Hospital Basel, University of Basel, Basel, Switzerland.
Förderung
- EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - E…
- Wellcome Trust
Zitieren
APA
Kurzeder, C., Nguyen-Sträuli, B. D., Krol, I., Ring, A., Castro-Giner, F., Nüesch, M., Asawa, S., Zhang, Y. W., Budinjas, S., Gvozdenovic, A., Vogel, M., Kohler, A., Grašič Kuhar, C., Schwab, F. D., Heinzelmann-Schwarz, V., Weber, W. P., Rochlitz, C., Vorburger, D., Frauchiger-Heuer, H., …, & Aceto, N. (2025). Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial. Nature Medicine, 31(4), 1120-1124. https://doi.org/10.1038/s41591-024-03486-6
Vancouver
Kurzeder C, Nguyen-Sträuli BD, Krol I, Ring A, Castro-Giner F, Nüesch M, et al. Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial. Nature Medicine. 2025;31(4):1120-1124. doi:10.1038/s41591-024-03486-6
BibTeX
@article{Kurzeder2025,
author = {Kurzeder, Christian and Nguyen-Sträuli, Bich Doan and Krol, Ilona and Ring, Alexander and Castro-Giner, Francesc and Nüesch, Manuel and Asawa, Simran and Zhang, Yu Wei and Budinjas, Selina and Gvozdenovic, Ana and Vogel, Maren and Kohler, Angela and Grašič Kuhar, Cvetka and Schwab, Fabienne D and Heinzelmann-Schwarz, Viola and Weber, Walter Paul and Rochlitz, Christoph and Vorburger, Denise and Frauchiger-Heuer, Heike and Witzel, Isabell and Wicki, Andreas and Kuster, Gabriela M and Vetter, Marcus and Aceto, Nicola},
title = {Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial},
journal = {Nature Medicine},
year = {2025},
volume = {31},
number = {4},
pages = {1120--1124},
doi = {10.1038/s41591-024-03486-6}
}
EUVIMED